Literature DB >> 15083376

Organization of the human aromatase p450 (CYP19) gene.

Serdar E Bulun1, Kazuto Takayama, Takashi Suzuki, Hironobu Sasano, Bertan Yilmaz, Siby Sebastian.   

Abstract

The human CYP19 (p450arom) gene is located in the 21.2 region on the long arm of chromosome 15 (15q21.2). This gene spans a region that consists of a 30 kb coding region and a 93 kb regulatory region ( approximately 123 kb total length). Its regulatory region contains at least 10 distinct promoters regulated in a tissue- or signaling pathway-specific manner. The Human Genome Project data published in 2000 enabled us to accurately align these promoters within the 93 kb regulatory region of the p450arom gene. Each promoter is regulated by a distinct set of regulatory sequences in DNA and transcription factors that bind to these specific sequences. In most vertebrates, p450arom expression is under the control of gonad- and brain-specific promoters. In humans, however, there are at least eight additional promoters that were apparently recruited throughout evolution, possibly via alterations in DNA. A critical mechanism that permits the use of such a large number of promoters seems to be the extremely promiscuous nature of the common splice acceptor site because, with activation of each promoter, an untranslated first exon is spliced onto this common junction immediately upstream of the translation start site in the coding region. These partially tissue-specific promoters are used in the gonads, bone, brain, vascular tissue, adipose tissue, skin, fetal liver, and placenta for estrogen biosynthesis necessary for human physiology. Ovary and testis use promoter II, which is located immediately upstream of the coding region. The adipose tissue in general, including adipose tissue of the disease-free breast, on the other hand, maintains low levels of aromatase expression primarily via promoter I.4, which lies 73 kb upstream of the common coding region. Promoters I.3 and II are used only minimally in normal breast adipose tissue. Promoter II and I.3 activities in breast cancer tissue, however, are strikingly increased. Additionally, the endothelial-type promoter I.7 is also upregulated in breast cancer. Therefore, breast tumor tissue takes advantage of four promoters (II, I.3, I.7, and I.4) for aromatase expression and estrogen production. The sum of p450arom mRNA species arising from these four promoters contributes significantly to elevated levels of total p450arom mRNA in breast cancer in contrast to the normal breast that uses promoter I.4. Because each mRNA species contains the identical coding region regardless of the variable untranslated first exon, the encoded protein functions as the aromatase enzyme in each case.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15083376     DOI: 10.1055/s-2004-823022

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  32 in total

1.  An aroma of complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors.

Authors:  Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2013-12       Impact factor: 5.958

2.  Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.

Authors:  Gurusamy Umamaheswaran; Steven Aibor Dkhar; Sekar Kalaivani; Raj Anjana; Mohan Revathy; Mohammad Jaharamma; Kulumani Mahadevan Lakshmi Shree; Dharanipragada Kadambari; Chandrasekaran Adithan
Journal:  Med Oncol       Date:  2013-07-28       Impact factor: 3.064

3.  Genomic basis of aromatase excess syndrome: recombination- and replication-mediated rearrangements leading to CYP19A1 overexpression.

Authors:  Maki Fukami; Takayoshi Tsuchiya; Heike Vollbach; Kristy A Brown; Shuji Abe; Shigeyuki Ohtsu; Martin Wabitsch; Henry Burger; Evan R Simpson; Akihiro Umezawa; Daizou Shihara; Kazuhiko Nakabayashi; Serdar E Bulun; Makio Shozu; Tsutomu Ogata
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

4.  Impact of aromatase genetic variation on hormone levels and global outcome after severe TBI.

Authors:  Julie A Garringer; Christian Niyonkuru; Emily H McCullough; Tammy Loucks; C Edward Dixon; Yvette P Conley; Sarah Berga; Amy K Wagner
Journal:  J Neurotrauma       Date:  2013-08-15       Impact factor: 5.269

5.  GnRH agonist and letrozole in women with recurrent implantation failure.

Authors:  Nidhi Sharma
Journal:  Ann Transl Med       Date:  2019-09

6.  Glucocorticoid-induction of hypothalamic aromatase via its brain-specific promoter.

Authors:  D C Brooks; H Zhao; M B Yilmaz; J S Coon V; S E Bulun
Journal:  Mol Cell Endocrinol       Date:  2012-06-13       Impact factor: 4.102

7.  Estradiol Synthesis in Gut-Associated Lymphoid Tissue: Leukocyte Regulation by a Sexually Monomorphic System.

Authors:  Oliver R Oakley; Kee Jun Kim; Po-Ching Lin; Radwa Barakat; Joseph A Cacioppo; Zhong Li; Alexandra Whitaker; Kwang Chul Chung; Wenyan Mei; CheMyong Ko
Journal:  Endocrinology       Date:  2016-10-25       Impact factor: 4.736

Review 8.  Adaptive evolution of mammalian aromatases: lessons from Suiformes.

Authors:  A J Conley; C J Corbin; A L Hughes
Journal:  J Exp Zool A Ecol Genet Physiol       Date:  2009-06-01

9.  Interaction of soy food and tea consumption with CYP19A1 genetic polymorphisms in the development of endometrial cancer.

Authors:  Wang Hong Xu; Qi Dai; Yong Bing Xiang; Ji Rong Long; Zhi Xian Ruan; Jia Rong Cheng; Wei Zheng; Xiao Ou Shu
Journal:  Am J Epidemiol       Date:  2007-09-07       Impact factor: 4.897

10.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Authors:  Zaida Garcia-Casado; Angel Guerrero-Zotano; Antonio Llombart-Cussac; Ana Calatrava; Antonio Fernandez-Serra; Amparo Ruiz-Simon; Joaquin Gavila; Miguel A Climent; Sergio Almenar; Jose Cervera-Deval; Josefina Campos; Carlos Vazquez Albaladejo; Antonio Llombart-Bosch; Vicente Guillem; Jose A Lopez-Guerrero
Journal:  BMC Cancer       Date:  2010-02-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.